Phase I Study of Induction Cisplatin, Docetaxel and Nintedanib for Stage IB-IIIA Non-small Cell Lung Cancers Amenable for Surgical Resection

Trial Profile

Phase I Study of Induction Cisplatin, Docetaxel and Nintedanib for Stage IB-IIIA Non-small Cell Lung Cancers Amenable for Surgical Resection

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Nintedanib (Primary) ; Cisplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Jan 2018 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
    • 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 02 Aug 2017 Planned End Date changed from 1 Jun 2020 to 1 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top